total revenue was only 4.9b in 2016 but their new drug dupixent has the potential to be worth up to 11b in revenues... add that to the fact they have other nice drugs in the pipeline is this stock ready for a move up?just want some peoples opinions
Submitted April 04, 2017 at 01:58PM by david687 http://ift.tt/2nB45dX
